



Curriculum Vitae

Personal Information

Title	Dr.	
Name	Jun Miyoshi	
Degree	MD, PhD	
Country	Japan	
Affiliation	Kyorin University School of Medicine	

Educational Background

2000-2006: Keio University School of Medicine (Tokyo, Japan); M.D.
 2008-2012: Graduate School of Medicine, Keio University (Tokyo, Japan); Ph.D.

Professional Experience

2006-2008: Residency, Kawasaki Municipal Hospital (Kanagawa, Japan)
 2008-2012: Clinical Fellow (M.D., Ph.D. Program), Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University Hospital (Tokyo, Japan)
 2012-2014: Clinical instructor, Department of Gastroenterology and Hepatology, Tokyo Dental College Ichikawa General Hospital (Chiba, Japan)
 2014-2019: Postdoctoral Scholar, Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, the University of Chicago (IL, U.S.A.)
 2019-2022: Senior Assistant Professor, Department of Gastroenterology and Hepatology, Kyorin University School of Medicine
 2022-present: Associate Professor, Department of Gastroenterology and Hepatology, Kyorin University School of Medicine

Professional Organizations

Japanese Society of Internal Medicine (Board certified)
 Japanese Society of Gastroenterology (Board certified)
 Japanese Gastroenterological Endoscopy Society (Board certified)
 The Japanese Gastroenterological Association (Board certified)
 American Gastroenterological Association (Microbiome and Microbial Therapy Nominating Committee)
 The Japanese Society for Mucosal Immunology (Councilor)
 The Japanese Society of Clinical Immunology (Chair of U45 Sub-Committee)
 Japanese Society of Inflammatory Bowel Disease (Educational Committee, Board System Committee)
 Asian Organization for Crohn's and Colitis
 European Crohn's and Colitis Organisation
 International Bowel Ultrasound Group
 Japan Society of Coloproctology
 Japanese Society of Medical Oncology

Main Scientific Publications



- 1 Frazier K, Kambal A, Zale EA, Pierre JF, Hubert N, Miyoshi S, **Miyoshi J**, Ringus DL, Harris D, Yang K, Carroll K, Hermanson JB, Chlystek JS, Overmyer KA, Cham CM, Musch MW, Coon JJ, Chang EB, Leone VA. High-fat diet disrupts REG3y and gut microbial rhythms promoting metabolic dysfunction. *Cell Host Microbe*. 2022;30(6):809-823.e6.
- 2 **Miyoshi J**, Ozaki R, Yonezawa H, Mori H, Kawamura N, Matsuura M, Hisamatsu T. Ratio of submucosal thickness to total bowel wall thickness as a new sonographic parameter to estimate endoscopic remission of ulcerative colitis. *J Gastroenterol*. 2022;57(2):82-89.
- 3 **Miyoshi J**, Matsuura M, Hisamatsu T. Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis. *Expert Opin Drug Saf*. 2022;21(1):1-8.
- 4 **Miyoshi J**, Hisamatsu T. The impact of maternal exposure to antibiotics on the development of child gut microbiome. *Immunol Med*. 2022;45(2):63-68.
- 5 Miura M, Shimizu H, Saito D, **Miyoshi J**, Matsuura M, Kudo T, Hirayama D, Yoshida M, Arai K, Iwama I, Nakase H, Shimizu T, Hisamatsu T. Multicenter, cross-sectional, observational study on Epstein-Barr viral infection status and thiopurine use by age group in patients with inflammatory bowel disease in Japan (EBISU study). *J Gastroenterol*. 2021;56(12):1080-1091.
- 6 **Miyoshi J**, Miyoshi S, Delmont TO, Cham C, Lee STM, Sakatani A, Yang K, Shan Y, Kennedy M, Kiefl E, Yousef M, Crosson S, Sogin M, Antonopoulos DA, Eren AM, Leone V, Chang EB. Early-Life Microbial Restitution Reduces Colitis Risk Promoted by Antibiotic-Induced Gut Dysbiosis in Interleukin 10-/ Mice. *Gastroenterology*. 2021;161(3):940-952.e15.
- 7 **Miyoshi J**, Lee STM, Kennedy M, Puertolas M, Frith M, Koval JC, Miyoshi S, Antonopoulos DA, Leone V, Chang EB. Metagenomic Alterations in Gut Microbiota Precede and Predict Onset of Colitis in the IL10 Gene-Deficient Murine Model. *Cell Mol Gastroenterol Hepatol*. 2021;11(2):491-502.
- 8 **Miyoshi J**, Maeda T, Matsuoka K, Saito D, Miyoshi S, Matsuura M, Okamoto S, Tamura S, Hisamatsu T. Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis. *Sci Rep*. 2021;11(1):16440.
- 9 **Miyoshi J**, Rao MC, Chang EB. Navigating the Human Gut Microbiome: Pathway to Success from Lessons Learned. *Gastroenterology*. 2020;159(6):2019-2024.
- 10 Basson AR, LaSalla A, Lam G, Kulpins D, Moen EL, Sundrud MS, **Miyoshi J**, Ilic S, Theriault BR, Cominelli F, Rodriguez-Palacios A. Artificial microbiome heterogeneity spurs six practical action themes and examples to increase study power-driven reproducibility. *Sci Rep*. 2020;10(1):5039.
- 11 **Miyoshi J**, Sofia MA, Pierre JF. The evidence for fungus in Crohn's disease pathogenesis. *Clin J Gastroenterol*. 2018;11(6):449-456.
- 12 **Miyoshi J**, Matsuoka K, Yoshida A, Naganuma M, Hisamatsu T, Yajima T, Inoue N, Okamoto S, Iwao Y, Ogata H, Ueno F, Hibi T, Kanai T. 5-aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis. *Intest Res*. 2018;16(4):635-640.
- 13 **Miyoshi J**, Leone V, Nobutani K, Musch MW, Martinez-Guryan K, Wang Y, Miyoshi S, Bobe AM, Eren AM, Chang EB. Minimizing confounders and increasing data quality in murine models for studies of the gut microbiome. *PeerJ*. 2018;6:e5166.
- 14 **Miyoshi J**, Qiao Y, Chang EB. The role of the intestinal microbiota in the pathogenesis and treatment of inflammatory bowel diseases. *Semin Colon Rectal Surg*. 2018;29:21-27.
- 15 **Miyoshi J**, Nobutani K, Musch MW, Ringus DL, Hubert NA, Yamamoto M, Kase Y, Nishiyama M, Chang EB. Time-, Sex-, and Dose-Dependent Alterations of the Gut Microbiota by Consumption of Dietary Daikenchuto (TU-100). *Evid Based Complement Alternat Med*. 2018;2018:7415975.
- 16 **Miyoshi J**, Bobe AM, Miyoshi S, Huang Y, Hubert N, Delmont TO, Eren AM, Leone V, Chang, EB. Peripartum exposure to antibiotics promotes persistent gut dysbiosis, immune imbalance, and inflammatory bowel disease in genetically prone offspring. *Cell Rep*. 2017;20(2):491-504.
- 17 **Miyoshi J**, Chang EB. The gut microbiota and inflammatory bowel diseases. *Transl Res*. 2017; 179: 38-48.